Abstract
Here, we develop a simple molecular test for SARS-CoV-2 in saliva based on reverse transcription loop-mediated isothermal amplification (RT-LAMP). The test has two steps: 1) prepare saliva with heat and a stabilization solution, and 2) detect virus by incubating with a primer and enzyme mix at 65°C for 30 minutes. After incubation, saliva samples containing the SARS-CoV-2 genome turn bright yellow, while the negative samples remain pink. Because this test is pH dependent, it can react falsely to naturally acidic human saliva. Here, we report unique buffering conditions and protocols that rendered 295 healthy human saliva samples compatible with the test, producing zero false positives. We also evaluated the test on 168 saliva samples from individuals infected with SARS-CoV-2, and from 47 matched pairs of saliva and anterior nasal samples from infected individuals. The Saliva TwoStep test described here reliably identified infected individuals with 94% sensitivity and >99% specificity.
Competing Interest Statement
Some of the authors of this study (NRM, QY, CLP, SLS) are founders of Darwin Biosciences, who licenses the RT-LAMP assay described herein.
Funding Statement
We thank the Burroughs Wellcome Fund (PATH award to SLS; PDEP award to NRM) and NIH (DP1-DA-046108 to SLS) for funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Colorado Boulder Institutional Review Board. Saliva samples for assay development were collected under protocol 20-0068. Testing on human subjects is aggregated data resulting from University of Colorado Boulder operational COVID-19 surveillance testing.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The analysis of infected human samples was included, authors were added.
Data Availability
All data is included in the manuscript.
